Various mechanisms have been postulated for the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on DKD, including activation of tubulo-glomerular feedback, decrease in the circulating levels of IL-6, TNF receptor-1, matrix metalloproteinase-7, and fibronectin-1, and reduced ketone production [84,86,102,103,104,105,106]. Here, SLC5A2 is linked to diabetic kidney disease.